Apple Inc. (AAPL)vs Novo Nordisk A/S (NVO)

Quick verdict

Apple Inc. (AAPL) and Novo Nordisk A/S (NVO) both carry an overall verdict grade of A across valuation, growth, quality, and balance sheet categories, though Apple leads on the composite overall score (5.5 versus 0.5) and momentum is scored a tie. Apple trades at a trailing PE of 39.4 versus Novo Nordisk's 58.77, and on a forward basis 26.84 versus 31.06, suggesting Apple is priced more moderately relative to near-term earnings expectations. Novo Nordisk offers a stronger free cash flow yield (5.83% versus 3.57%) and higher 3-year revenue CAGR (13.22% versus 6.43%), while Apple shows substantially higher 5-year revenue CAGR (29.32% versus 10.58%) and far higher returns on equity (146.69% versus 17.27%). Both stocks are tagged for value, growth, income, and quality investor profiles, with Apple styled as high-quality and Novo Nordisk as high-volatility, reflecting its higher beta of 1.8 versus 1.097.

2-year relative performance

At-a-glance comparison

Business model and revenue mix

Apple Inc. operates in the Technology sector, specifically Consumer Electronics, designing and selling a diverse range of electronic devices globally. Its business spans hardware alongside services, generating a gross margin of 47.86% and an operating margin of 32.64%. Novo Nordisk A/S operates in the Healthcare sector as a Drug Manufacturer, with a comparable gross margin of 48.37% but a considerably lower operating margin of 12.93%, indicating a different cost structure typical of pharmaceutical R&D and commercialisation. Despite the operating margin gap, Novo Nordisk posts a higher net margin (32.6% versus 27.15%), reflecting differences in below-the-line items such as tax and financing costs. Apple's market capitalisation of approximately $4.80 trillion dwarfs Novo Nordisk's $48.15 billion, placing the two companies in very different size tiers despite both trading on exchanges tracked here as NASDAQ-listed.

Valuation

On trailing earnings, Apple trades at a PE of 39.4 compared with Novo Nordisk's 58.77, while forward PE narrows the gap to 26.84 versus 31.06, implying the market expects faster near-term earnings growth normalisation for Novo Nordisk. Price-to-sales tells a similar story, with Apple at 10.63 versus Novo Nordisk's 17.63. However, price-to-book strongly favours Novo Nordisk at 13.98 against Apple's 45.12, and EV/EBITDA is broadly comparable at 30.22 versus 30.66. Apple's PEG ratio of 1.36 is lower than Novo Nordisk's 1.83, suggesting Apple's valuation is more supported by its earnings growth trajectory. Free cash flow yield favours Novo Nordisk at 5.83% versus Apple's 3.57%, indicating relatively more cash generation per dollar of market value. Both carry an A verdict grade for valuation, reflecting reasonable positioning relative to their respective growth and quality profiles.

Growth profile

Growth metrics show divergent patterns across timeframes. Apple's 3-year revenue CAGR of 6.43% trails Novo Nordisk's 13.22%, but Apple's 5-year revenue CAGR of 29.32% far exceeds Novo Nordisk's 10.58%, indicating a stronger longer-term revenue expansion phase for Apple. On earnings, Apple's 3-year EPS CAGR of 22.59% and 5-year EPS CAGR of 39.1% both outpace Novo Nordisk's 10.44% and 14.15% respectively. This suggests Apple has demonstrated more pronounced earnings scaling over the medium to long term, while Novo Nordisk's growth has been comparatively steadier but slower. Both companies received an A verdict for growth, reflecting that each has delivered growth considered strong relative to their sector peers, despite the underlying differences in magnitude and consistency between the two revenue and earnings trajectories shown in the data.

Profitability and quality

Apple demonstrates markedly higher returns on capital, with return on equity of 146.69% and return on invested capital of 49.57%, compared with Novo Nordisk's 17.27% ROE and 30.17% ROIC. Apple's operating margin of 32.64% is more than double Novo Nordisk's 12.93%, though gross margins are closely matched at 47.86% for Apple versus 48.37% for Novo Nordisk. Novo Nordisk's net margin of 32.6% exceeds Apple's 27.15%, showing that despite thinner operating margins, its bottom-line conversion remains strong. Both companies carry an A verdict for quality and income categories, but the scale of Apple's ROE and ROIC figures points to a more capital-efficient structure, potentially influenced by its balance sheet composition, buyback activity, and asset base relative to Novo Nordisk's pharmaceutical-oriented capital deployment.

Balance-sheet risk

Apple holds cash of approximately $67.92 billion against total debt of $76.23 billion, yielding a net debt/EBITDA of -1.5, indicating net cash relative to earnings when adjusted per the data provided. Novo Nordisk holds cash of $30.27 billion against total debt of $21.63 billion, but its net debt/EBITDA reading of 4.18 suggests a different leverage calculation basis in the underlying data. Apple's current ratio of 1.07 is lower than Novo Nordisk's 2.55, indicating Novo Nordisk holds proportionally more short-term liquidity against current liabilities. Interest coverage strongly favours Novo Nordisk at 42.78 versus Apple's 3.19, suggesting Novo Nordisk's operating income covers interest obligations more comprehensively. Both companies nonetheless received an A verdict for balance sheet strength, reflecting adequate financial footing overall despite these structural differences in liquidity and coverage ratios.

Price performance and shareholder returns

Year-to-date, Apple has returned 58.09% compared with Novo Nordisk's 12.84%, while over one year the two are closer, with Novo Nordisk at 76.32% versus Apple's 73.53%. Over three years annualised, Novo Nordisk edges ahead at 30.35% versus Apple's 27.16%, though both show negative 5-year annualised returns, at -0.6% for Apple and -3.07% for Novo Nordisk. Maximum drawdown over five years has been considerably deeper for Novo Nordisk at -44.33% compared with Apple's -19.47%, consistent with Novo Nordisk's higher beta of 1.8 versus Apple's 1.097 and its high-volatility style tag. Momentum is scored as a tie between the two. These figures collectively suggest Novo Nordisk has experienced sharper drawdowns and higher volatility alongside periods of comparable or superior returns over certain windows.

Which stock fits which investor

Based on the bestFor verdict tags, both Apple and Novo Nordisk are flagged as suitable considerations across value, growth, income, and quality-oriented profiles. Investors focused on capital efficiency metrics such as ROE of 146.69% and ROIC of 49.57%, alongside a lower PEG ratio of 1.36, may find Apple's profile aligned with a high-quality style tag. Those more attentive to free cash flow yield (5.83%), interest coverage (42.78), and current ratio (2.55) may note Novo Nordisk's balance sheet liquidity strengths, though its high-volatility style tag and -44.33% maximum drawdown reflect greater historical price swings. Income-oriented considerations differ notably, as Apple offers a dividend yield of 0.32% against Novo Nordisk's 0%, though Novo Nordisk's payout ratio of 36.3% exceeds Apple's 12.69%. This is not investment advice.

• Value: AAPL
• Growth: AAPL
• Income: AAPL
• Quality: AAPL

Frequently asked questions

How do Apple and Novo Nordisk compare on valuation?

Apple trades at a trailing PE of 39.4 and forward PE of 26.84, while Novo Nordisk trades at a trailing PE of 58.77 and forward PE of 31.06. Apple's price-to-book of 45.12 is notably higher than Novo Nordisk's 13.98, while Novo Nordisk's free cash flow yield of 5.83% exceeds Apple's 3.57%. Both received an A verdict for valuation.

Which company has grown faster?

Over 5 years, Apple's revenue CAGR of 29.32% and EPS CAGR of 39.1% substantially exceed Novo Nordisk's 10.58% and 14.15% respectively. Over 3 years, Novo Nordisk's revenue CAGR of 13.22% is higher than Apple's 6.43%, though Apple's 3-year EPS CAGR of 22.59% remains ahead of Novo Nordisk's 10.44%.

Which stock has been more volatile?

Novo Nordisk carries a higher beta of 1.8 compared with Apple's 1.097, and its 5-year maximum drawdown of -44.33% is considerably deeper than Apple's -19.47%. This aligns with Novo Nordisk's high-volatility style tag versus Apple's high-quality style tag.

How do their balance sheets differ?

Apple holds $67.92 billion in cash against $76.23 billion in total debt, with a current ratio of 1.07 and interest coverage of 3.19. Novo Nordisk holds $30.27 billion in cash against $21.63 billion in debt, with a current ratio of 2.55 and interest coverage of 42.78. Both received an A verdict for balance sheet strength.

Related comparisons

• AAPL vs AMD
• AAPL vs AMZN
• AAPL vs AVGO
• AAPL vs BABA
• AAPL vs BAC
• AAPL vs COIN